Peer Review History
| Original SubmissionOctober 14, 2022 |
|---|
|
PONE-D-22-28431Metastability as a neuromechanistic biomarker of schizophrenia pathologyPLOS ONE Dear Dr. Hancock, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Feb 02 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Daqing Guo Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized. Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access. We will update your Data Availability statement to reflect the information you provide in your cover letter. 3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide. 4. Thank you for stating the following in the Competing Interests/Financial Disclosure * (delete as necessary) section: “RM 200/02/Z/15/Z Wellcome Trust Career Development fellowship https://wellcome.org/grant-funding/schemes/career-development-awards JC UIDB/50026/2020, UIDP/50026/2020 and CEECIND/03325/2017 Portuguese Foundation for Science and Technology https://3bs.uminho.pt/research-projects FET National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King’s College London OD National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King’s College London The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.” We note that you received funding from a commercial source: “Wellcome Trust” Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc. Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf. 5. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section. 6. Thank you for stating the following in the Competing Interests section: “I have read the journal's policy and the authors of this manuscript have the following competing interests: RM has received honoraria for educational talks from Otsuka and Janssen” Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes Reviewer #3: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: In this study, the authors applied Leading Eigenvector Dynamic Analysis (LEiDA) to capture specific features of dynamic functional connectivity and then implements a novel approach to estimate metastability. They found that the new approach was capable of discriminating cases from controls with elevated effect sizes relative to published literature, reflected in an up to 76% area under the curve (AUC) in out-of-sample classification analyses. Furthermore, their analyses showed that patients with early psychosis exhibit intermittent disconnectivity of subcortical regions with frontal cortex and cerebellar regions, introducing new insights about the mechanistic bases of these conditions. These results demonstrate reliability and face validity of metastability as a neuromechanistic biomarker of schizophrenia pathology. The paper is overall well-written. Nevertheless, there are still a few issues to be addressed. Questions: 1) (Introduction p1) The authors only briefly introduced schizophrenia, please elaborate on the symptoms of schizophrenia, such as those related to the disconnection hypothesis, and the authors said that "Biomarkers of schizophrenia in early and established phases may differ, …", which also needs to be explained in detail. 2) (Introduction p4) I noted that the authors analyzed the suitability of a specific marker of brain dynamics: metastability, which is a ubiquitous concept across diverse models of brain functioning including coordination dynamics and complex systems. Please elaborate on the reasons for choosing it and its advantages over commonly used dynamic metrics. 3) (Method) Statistical methods should be used to examine whether there are between-group differences in the demographic characteristics of the participants. 4) (Method) Covariate removal was not performed in the preprocessing of Cobre data. Would this affect subsequent analyses? 5) I found some typographical and word errors. Please check the manuscript carefully. For example, ‘mm2, mm3’ and ‘… an ubiquitous’. 6) (Discussion) “…, This may reflect that the cases in HCPEP are in the early stages of schizophrenia whilst the cases in Cobre are in a well-established stage of schizophrenia.” In fact, the age of participants in HCPEP and Cobre datasets was quite different, whether this would affect the validation between the two datasets. Reviewer #2: Hancock and colleagues examined whether metastability derived from resting-state fMRI can be used as a mechanistic biomarker of schizophrenia, including a demonstration of reliability and face validity. To this end, using two datasets from the HCP Early Psychosis (HCPEP) and Cobre, they applied Leading Eigenvector Dynamic Analysis (LEiDA) technique to capture specific features of dynamic functional connectivity and then introduced a novel approach to estimate metastability. They achieved an AUC of 76% in the classification analysis and found patients with early psychosis show intermittent disconnectivity of subcortical regions with frontal cortex and cerebellar regions. The topic of the paper is of interest, but I have some suggestions to improve the paper’s likely reach and impact: One concern I have is about the novelty of the methods presented. The authors claimed that it is a “new” approach, but one of the coauthors (Cabral and colleagues, 2017) has already published the very similar work. Her previous work introduced a series of steps (e.g., phase-locking based FC and iPL computation) to apply LEiDA approach to fMRI data. The cited paper by Cabral et al. already presents large parts of the current methods and results. My understanding is that the authors used the existing methods. So, it is not clear what is “new” approach compared to previous work by Cabral et al.. What is the novelty of this work in terms of methodology? Just difference in metastability as the mean variance of instantaneous phase-locking, VAR compared to the conventional metastability? What if we used the traditional metastability values in analyses? This metastability metric cannot be used as a biomarker of schizophrenia? Supporting evidence to claim it as a biomarker of SCZ should be provide in more detail. At current form, it sounds over-claimed statement/conclusion given a small number of samples (patients with SCZ and early psychosis). Also, I encourage to compare the results by a “new” metastability and those by a “conventional” metastability in analyses, including experiments to provide the insight about a mechanistic explanation as well as classification ability. Is there any difference in metastability due to the choice of resting-state networks? As described in the paper, one can choose pre-defined resting-state network extracted with ICA, network masks or functional template. First, why the authors chose data-driven approach rather than the existing ones? Second, the choice of the template to define different resting-state networks affected the classification ability? As an additional concern, I noted that metastability for each network was computed as the mean value of the variance of instantaneous phase-locking over time in each community/network. Different communities have different number of brain ROIs included in analysis. Synchrony across a large number of ROIs in a community/network will have a smaller variance. In this sense, I am somewhat unsurprised that these networks demonstrate lower levels of both metastability and synchrony in comparison to other networks with smaller number of ROIs. This is a factor that should be included in the statistical analysis to ensure the robustness of this result. This should be discussed in the discussion. In building machine learning classifier using metastability measures, first of all, I wondered why the authors chose a naïve Bayes model rather than other common models such as support vector machine or logistic regression. I am curious whether the authors considered other machine learning classifiers and tested to evaluate the performance of the binary classification (SCZ vs. controls). Second, were there any pre-processing step prior to building a machine learning classifier such as standardization or min-max scaling and so on. Third, when using a naïve Bayes model, how to tune the hyperparameters to obtain optimal parameters that may provide best performance in classification. Fourth, why doswnsampling? This may lead to overfitting due to smaller number of subjects in controls and SCZ. I was wondering if up-sampling approach to the samples has been considered to make the samples balanced. In terms of evaluating the performance of the classifier, the authors used the HCPEP as a training set and the Cobre as a testing set and vice versa for the out-of-sample analysis. Table 4 shows the results of out-of-sample testing for both scenarios. Can you provide more detailed discussion on why the results are different due to the choice of which training sample was used. Overall, a classifier trained on Cobre sample provided better performance than the other case. Any discussion on these results? Further, given a balanced datasets downsampled, the results by classification are not good in terms of accuracy (0.38-0.57) and other measures as well. Why? I like the way of testing the machine learning model by using different, independent samples. Have the authors ever tested the classification performance within each sample, although the sample size is quite small? Reviewer #3: In this article, the preprocessed data of HCPEP and Cobre datasets were applied the Hilbert transform, and the authors introduced a new method of Leading Eigenvector Dynamic Analysis (LEiDA) in the frequency domain to capture the specific features of dynamic functional connectivity and then implemented a novel approach to estimate the metastability. Finally, the control group and cases group were classified by a naïve Bayes classifier. Due to the unclear description of the method, there may be some problems with the results. Some comments are listed as follows: 1.There are several places where the data are not clear. (1) The number of healthy controls and patients in the abstract is not consistent with that in the manuscript. (2) Line 817, page 36: Which five datasets do they refer to? 2.Line 702, page 31: “3 conditions x 4 runs” refers to unknown. If “3 conditions” refers to the healthy control group, non-affective psychosis, and schizophrenia respectively, image acquisition in the text only describes that there are 4 runs in the HCPEP dataset, while there are no 4 runs in Cobre dataset for the healthy control group and schizophrenia patients. 3.Line 732 indicates that S7 is included in the supplementary materials, but it is not. 4.The demographic characteristics of participant groups should include the subject information that meets the inclusion criteria of the experiment. In addition, statistical comparisons can be made on information such as gender and age of different groups to show whether there are significant differences between groups in terms of gender and age. 5.There are three minor problems. (1) The full name of fMRI should appear once in the full text, such as the abstract. (2) The full text does not indicate that iPL is the abbreviation of instantaneous phase-locking. (3) There are some grammar problems in the article. Please check the grammar carefully. For example, it appears that you are missing a comma after the introductory phrase “In this study”. Consider adding a comma (Line 39, page 3). And it seems that the verb “implements” does not agree with the subject. Consider changing the verb form (Line 49, page 3). ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Metastability as a candidate neuromechanistic biomarker of schizophrenia pathology PONE-D-22-28431R1 Dear Dr. Hancock, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Daqing Guo Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: The revised version of the paper entitled "Metastability as a candidate neuromechanistic biomarker of schizophrenia pathology" was reviewed. Thank you for addressing my comments. I have no further comments and suggestions. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** |
| Formally Accepted |
|
PONE-D-22-28431R1 Metastability as a candidate neuromechanistic biomarker of schizophrenia pathology Dear Dr. Hancock: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Daqing Guo Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .